Navigation Links
Nektar to Announce Financial Results for the First Quarter of 2009 on Wednesday, May 6, 2009, After Close of U.S.-Based Financial Markets
Date:4/29/2009

SAN CARLOS, Calif., April 29 /PRNewswire-FirstCall/ -- Nektar Therapeutics (Nasdaq: NKTR) will announce its financial results for the first quarter ended March 31, 2009 on Wednesday, May 6, 2009, after the close of U.S.-based financial markets. Howard Robin, president and chief executive officer, will host a conference call to review the results beginning at 5:00 p.m. Eastern Time (ET)/2:00 p.m. Pacific Time (PT).

The press release and a live audio-only Webcast of the conference call can be accessed through a link that is posted on the home page and Investor Relations section of the Nektar website: http://www.nektar.com. The web broadcast of the conference call will be available for replay through Wednesday, May 20, 2009.

        To access the conference call, follow these instructions:

        Dial: (888) 396-2369 (U.S.); (617) 847-8710 (international)
        Passcode: 82263149 (Howard Robin is the host)

An audio replay will also be available shortly following the call through Wednesday, May 20, 2009 and can be accessed by dialing (888) 286-8010 (U.S.); or (617) 801-6888 (international) with a passcode of 19053055.

In the event that any non-GAAP financial measure is discussed on the conference call that is not described in the press release, related information will be made available on the Investor Relations page at the Nektar website as soon as practical after the conclusion of the conference call.

About Nektar

Nektar Therapeutics is a biopharmaceutical company developing novel therapeutics based on its advanced polymer conjugation technology platforms. Nektar's technology and drug development expertise have enabled nine approved products for partners, which include leading biopharmaceutical companies. Nektar is also developing a robust pipeline of its own potentially high-value therapeutics that addresses unmet medical needs by leveraging and expanding its technology platforms to improve and enable molecules. More information on Nektar is available at http://www.nektar.com

                Jennifer Ruddock, 650-631-4954, Nektar Therapeutics


'/>"/>
SOURCE Nektar Therapeutics
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. Nektar Therapeutics Repurchases $100 Million of Convertible Debt and Reports Third Quarter 2008 Financial Results
2. Nektar to Announce Financial Results for the Third Quarter of 2008 on Thursday, November 6, 2008 After Close of U.S.-Based Financial Markets
3. Nektar Therapeutics Announces Second Quarter 2008 Results
4. Nektar Therapeutics Names Randall Moreadith, M.D., Ph.D. Senior Vice President, Drug Development and Chief Development Officer
5. Nektar Therapeutics Announces First Quarter 2008 Results
6. FDA Approval of Cimzia(R) for Crohns Disease Represents Latest Milestone for Nektars PEGylation Technology Platform
7. Nektar Therapeutics Announces Fourth Quarter and Year-End 2007 Financial Results
8. Nektar to Announce 2007 Year-End Financial Results on Wednesday, February 27, 2008, After Close of U.S.-Based Financial Markets
9. Nektar Therapeutics President and CEO, Howard W. Robin, to Present at Merrill Lynch 19th Global Pharmaceutical, Biotechnology & Medical Device Conference in New York City
10. Nektar Announces Agreement With Baxter to Develop New PEGylated Therapeutics for Hemophilia
11. Nektars Leading PEGylation and Pulmonary Technology Platforms Featured at R&D Day in New York
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/10/2016)... (PRWEB) , ... December 10, 2016 , ... When faced ... worried about germs spreading from the seat to her body, and contamination of children ... and effective way to solve this problem that many people face. , The patent-pending ...
(Date:12/9/2016)... (PRWEB) , ... December 09, 2016 , ... ... planning assistance from offices in Pasco and Richland, is initiating a charity drive ... serious injuries resulting from a recent automobile collision. , On October 29th ...
(Date:12/9/2016)... ... December 09, 2016 , ... ... pharmaceutical inserts and outserts. As a means of expanding capabilities Flottman has ... enable Flottman to individually code professional inserts (PIs) and patient package inserts (PPIs) ...
(Date:12/9/2016)... ... 09, 2016 , ... The Justin Veatch Fund announced Thursday that ... the film Whispering Spirits and its discussion guide for use by all ... tool in the war against teen drug abuse. NCADD is the oldest anti-addiction ...
(Date:12/9/2016)... ... December 09, 2016 , ... An inventor from Cana, Va., wanted ... all types of amusement park rides. , The patent-pending SAFETY STRAP FOR AMPUTEES improves ... use and could be set up in a matter of minutes, or even seconds. ...
Breaking Medicine News(10 mins):
(Date:12/8/2016)... 2016 Research and Markets has announced the addition of ... offering. ... This report analyzes the worldwide markets for Endodontic Supplies in US$ Thousand. ... , Japan , Europe , ... Annual estimates and forecasts are provided for the period 2015 through ...
(Date:12/8/2016)... 8, 2016   TriNetX , the health ... Hospital signed a membership agreement to join ... of new cures. The TriNetX network ... million patients globally, biopharmaceutical companies and contract research ... protocol design, site selection, patient recruitment, and collaborative ...
(Date:12/8/2016)... LAVAL, Quebec , Dec. 8, 2016 /PRNewswire/ ... and TSX: VRX) ("Valeant") today announced positive ... vehicle-controlled clinical study to assess the safety and ... in the treatment of plaque psoriasis. ... adult subjects with moderate to severe psoriasis, IDP-118 ...
Breaking Medicine Technology: